While Celularity’s Biovance® and Biovance 3L products remained eligible for Medicare coverage under the now-withdrawn LCDs, Celularity CEO Dr. Robert…
October 31, 2025 16:30 ET | Source: FibroBiologics, Inc. Advancing preparations to begin manufacturing of fibroblast-based spheroids product candidate, CYWC628,…